ArticleInfluenza and other respiratory viruses2025
The National Burden of Influenza-Associated Respiratory Illness Among Children Aged <5 Years in Niger, 2015-2018.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The National Burden of Influenza-Associated Respiratory Illness Among Children Aged <5 Years in Niger, 2015-2018.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInfluenza contributes substantially to severe acute respiratory infection (SARI) morbidity and mortality worldwide. However, few countries have estimated influenza disease burden, especially middle and low-income countries. Burden data are important to understand the impacts of illness on the population and to inform interventions. Currently, Niger has no recommendations for seasonal influenza vaccination or antiviral use. We estimated the national number and rates of SARI and influenza-associated SARI hospitalizations, mild/moderate illness, and death among children aged < 5 years in Niger.
methodsWe utilized influenza surveillance data among children aged < 5 years hospitalized with SARI at three sentinel hospitals located in Niamey during 2015-2018 along with estimated catchment area population data to calculate the influenza-associated SARI hospitalization rates per 100,000 population. Rates were calculated for age groups < 1, 1-4, and < 5 years using the World Health Organization (WHO) methods and a hospital admission survey; then, we extrapolated the estimates nationally. We also used the influenza burden pyramid tool developed by WHO and the John Hopkins Center for Health Security to estimate influenza-associated mild/moderate illnesses and influenza-associated deaths for Niger.
resultsInfluenza viruses were detected in 175/1796 (9.7%) specimens collected and tested during the study period from children aged < 5 years at the three SARI sentinel surveillance sites. The influenza percentage positive was 7.7% (58/754) among infants aged < 1 year and 11.3% (117/1038) among children aged 1-4 years. The estimated mean annual national number of SARI hospitalizations among children aged < 5 years was 16,406 (95% CI: 15,117-17,779) and the estimated SARI hospitalization rate per 100,000 population was 405.3 (95% CI: 373.5-439.2). The estimated mean annual national number of influenza-associated SARI hospitalizations among children aged < 5 years was 1484 (95% CI: 1162-1813; rate: 36.7; 95% CI: 28.7-44.8). The estimated mean annual national number of influenza-associated mild illnesses, hospitalized patients, and deaths among children aged < 5 years in Niger was 218,030 (95% CI: 43,303-527,236), 1261 (95% CI: 38-3271), 223 (95% CI: 22-614), and 15 (95% CI: 6-373) respectively.
conclusions'This study estimated a substantial influenza disease burden among children aged < 5 years in Niger, highlighting, for decision makers, the importance of resource allocation and public health interventions like vaccination. Future efforts should consider estimating the potential cost-benefit of implementing prevention and control measures (e.g., influenza vaccine or antivirals) among children aged 6-59 months in Niger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.